natgillin/translations-raw huggingface dataset:
(APC-) resistance, antithrombin-III deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinemia, and antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant)
5 S, hiperhomocisteinemija in antifosfolipidna protitelesa (antikardiolipinska protitelesa, lupus antikoagulant),
- Known or suspected carcinoma of the breast
- znani karcinom dojke ali sum nanj,
- Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia
- karcinom endometrija ali drugi znani, od estrogena odvisni tumorji ali sum nanje,
- Abnormal liver function related to acute or chronic hepatocellular disease
- motnje v delovanju jeter, povezane z akutno ali kronično hepatocelularno boleznijo,
- Hepatic adenomas or carcinomas
- jetrni adenomi ali karcinomi,
- Undiagnosed abnormal genital bleeding
- nediagnosticirana nenormalna krvavitev iz rodil.
EVRA is not indicated during pregnancy (see section 4.6).
Med nosečnostjo uporaba obliža EVRA ni indicirana (glejte poglavje 4. 6).
If any of the conditions/ risk factors mentioned below is present, the benefits of the use of EVRA should be weighed against the possible risks for each individual woman and discussed with the woman before she decides to start using EVRA.
V prisotnosti kateregakoli od spodaj omenjenih stanj/ dejavnikov tveganja, je treba pri vsaki posameznici pretehtati koristi in morebitna tveganja uporabe obliža EVRA in se o tem z njo pogovoriti, še preden se odloči, ali ga bo uporabljala.
In the event of aggravation, exacerbation or first appearance of any of these conditions or risk factors, the woman should be emphatically told to contact her physician who will decide on whether its use should be discontinued.
Ženski moramo jasno povedati, naj v primeru poslabšanja, eksacerbacije ali prvega pojava kateregakoli od teh stanj ali dejavnikov tveganja obišče svojega zdravnika, ki bo odločil, ali mora z uporabo obliža prekiniti.
Thromboembolic and other vascular disorders
Tromboembolija in druge žilne bolezni
The use of any combined hormonal contraceptive, including EVRA, carries an increased risk of venous thromboembolism (deep vein thrombosis, pulmonary embolism) compared to no use.
Pri ženskah, ki uporabljajo katerokoli kombinirani hormonski kontraceptiv, vključno z obližem EVRA, je tveganje za vensko tromboembolijo (globoka venska tromboza, pljučna embolija) večje, kot če ga ne bi uporabljale.
Epidemiological studies have shown that the incidence of venous thromboembolism (VTE) in women with no other risk factors for VTE who use low dose oestrogen (< 50 micrograms ethinyl estradiol) combined contraceptives ranges from about 20 to 40 cases per 100,000 women-years, but this risk estimate varies according to the type of progestagen.
Ta ocena tveganja niha glede na vrsto progestagena.
This compares with 5 to 10 cases per 100,000 women-years for non-users and 60 cases per 100,000 pregnancies.
Navedeno tveganje je primerljivo s 5 do 10 primeri na 100. 000 žensk- let pri ženskah, ki ne uporabljajo hormonskih kontraceptivov in 60 primeri na 100. 000 nosečnosti.
VTE is fatal in 1%-2% of cases.
V 1- 2% primerov se VTE konča s smrtjo.
Data from a retrospective cohort study in women aged 15 to 44 years have suggested that the incidence of VTE in women who used EVRA is increased in comparison with users of a levonorgestrel-containing OC (so-called “ second generation” OC).
Podatki iz retrospektivne kohortne študije pri ženskah starih 15 do 44 let kažejo, da je pojavnost VTE pri ženskah, ki so uporabljale obliž EVRA, v primerjavi z uporabnicami peroralnih hormonskih kontraceptivov z levonorgestrelom (tako imenovani peroralni hormonski kontraceptivi “ druge generacije ”) povečana.
The incidence was 1.4 fold (95% CI 0.9-2.3) increased in women with or without other risk factors for VTE and 1.5 fold (95% CI 0.8-2.7) increased in women with no other risk factors for VTE.
Pojavnost VTE je bila 1, 4- kratno (95% CI 0, 9- 2, 3) povečana pri ženskah, z ali brez drugih dejavnikov tveganja za VTE in 1, 5- kratno (95% CI 0, 8- 2, 7) povečana pri ženskah brez drugih dejavnikov tveganja.
Epidemiological studies have also associated the use of combined oral contraceptives (COCs) with an increased risk for arterial (myocardial infarction, transient ischaemic attack, stroke) thromboembolism.
Epidemiološke študije so povezale tudi uporabo kombiniranih peroralnih hormonskih kontraceptivov s povečanim tveganjem za arterijsko (miokardni infarkt, tranzitorna ishemična ataka, kap) tromboembolijo.
Extremely rarely, thrombosis has been reported to occur in other blood vessels e. g., hepatic, mesenteric, renal, cerebral or retinal veins and arteries, in COC users.
Poročali so, da se pri ženskah, ki jemljejo KPKS, tromboza izjemno redko pojavi v drugih krvnih žilah npr. v venah in arterijah jeter, prebavil, ledvic, možganov ali mrežnice.
There is no consensus as to whether the occurrence of these events is associated with the use of COCs.
Ni enotnega mnenja, da je pojavnost teh dogodkov povezana z uporabo KPKS.
Symptoms of venous or arterial thrombosis can include:
Simptomi venske ali arterijske tromboze lahko vključujejo:
- Unilateral leg pain, and/ or swelling
- bolečino v eni nogi, in/ ali otekanje,
- Sudden severe pain in the chest with possible radiation to the left arm
- nenadno ostro bolečino v prsih, ki se lahko širi v levo roko,
- Sudden breathlessness, sudden onset of coughing without a clear cause
- nenadno zasoplost, nenaden napad kašlja brez pravega vzroka,
- Any unusual, severe, prolonged headache
- kakršenkoli neobičajen, hud, dolgotrajen glavobol,
- Sudden partial or complete loss of vision
- nenadno delno ali popolno izgubo vida,
- Diplopia
- diplopijo,
- Slurred speech or aphasia
- nerazločno govorjenje ali afazijo,
- Vertigo; collapse with or without focal seizure
- vrtoglavico; kolaps z ali brez fokalnega krča,
- Weakness or very marked numbness suddenly affecting one side or one part of the body
- slabost ali zelo izrazito odrevenelost, ki nenadoma prizadene eno stran ali en del telesa,
- Motor disturbances
- motnje gibanja,
- ‘ Acute’ abdominal pain
- ‘ akutno ’ bolečino v trebuhu.
The risk of venous thromboembolism in combined contraceptives users increases with:
Tveganje za vensko tromboembolijo se pri ženskah, ki uporabljajo kombinirane kontraceptive, povečuje s:
- Increasing age
- starostjo,
- A positive family history (i. e. venous thromboembolism ever in a sibling or parent at relatively
- pozitivno družinsko anamnezo, (npr. če se je pri bratu/ sestri ali staršu venska tromboembolija
early age).
pojavila že relativno zgodaj).
If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any hormonal contraceptive use
Če sumimo, da ima ženska dedno predispozicijo, jo moramo (preden se odloči za uporabo kateregakoli hormonskega kontraceptiva) za nasvet napotiti k specialistu,
- Prolonged immobilisation, major surgery to the legs, or major trauma.
- daljšo imobilizacijo, večjim kirurškim posegom na nogah ali hudo poškodbo.
In these situations it is
V teh primerih je
advisable to discontinue use (in the case of elective surgery at least 4 weeks in advance) and not to resume until two weeks after complete remobilisation
priporočljivo, da ženska z uporabo preneha (vsaj 4 tedne pred predvidenim kirurškim posegom) in z njo nadaljuje šele 2 tedna po popolni remobilizaciji,
- Obesity (body mass index over 30 kg/ m²)
- debelostjo (indeks telesne mase nad 30 kg/ m²),
- Possibly also with superficial thrombophlebitis and varicose veins.
- možno tudi s površinskim tromboflebitisom in varicami.
There is no consensus about
Ni enotnega mnenja o možni vlogi teh
the possible role of these conditions in the aetiology of venous thrombosis.
stanj pri etiologiji venske tromboze.
The risk of arterial thromboembolic complications in combined contraceptives users increases with:
Tveganje za arterijske trombembolične zaplete se pri ženskah, ki uporabljajo kombinirane kontraceptive, povečuje s:
- Increasing age;
- starostjo,
- Smoking (with heavier smoking and increasing age the risk further increases, especially in
- kajenjem (tveganje se še poveča pri strastnih kadilkah in s starostjo, predvsem pri ženskah,
women over 35 years of age);
starejših od 35 let),
- Dyslipoproteiniaemia;
- dislipoproteinemijo,
- Obesity (body mass index over 30 kg/ m²);
- debelostjo (indeks telesne mase nad 30 kg/ m²),
- Hypertension;
- hipertenzijo,
- Valvular heart disease;
- boleznijo srčnih zaklopk,
- Atrial fibrillation;
- fibrilacijo preddvorov,
- A positive family history (arterial thrombosis ever in a sibling or parent at a relatively early
- pozitivno družinsko anamnezo (če se je pri bratu/ sestri ali staršu arterijska tromboza pojavila že
age).
relativno zgodaj).
If a hereditary predisposition is suspected, the woman should be referred to a specialist for advice before deciding about any hormonal contraceptive use.
Če sumimo, da ima ženska dedno predispozicijo, jo moramo (preden se odloči za uporabo kateregakoli hormonskega kontraceptiva) za nasvet napotiti k specialistu.
Biochemical factors that may be indicative of hereditary or acquired predisposition for venous or arterial thrombosis include Activated Protein C (APC) resistance, hyper homocysteinaemia, antithrombin-III deficiency, protein C deficiency, protein S deficiency, antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant).
Biokemični faktorji, ki lahko kažejo na dedno ali pridobljeno predispozicijo za vensko ali arterijsko trombozo, vključujejo rezistenco za aktivirani protein C (APC), hiperhomocisteinemijo, pomanjkanje antitrombina III, pomanjkanje proteina C, pomanjkanje proteina S, antifosfolipidna protitelesa (antikardiolipinska protitelesa, lupus antikoagulant).
Other medical conditions, which have been associated with adverse circulatory events, included diabetes mellitus, systemic lupus erythematosus, haemolytic uraemic syndrome, chronic inflammatory bowel disease (e. g., Crohn’ s disease or ulcerative colitis).
Crohnova bolezen ali ulcerozni kolitis).
The increased risk for thromboembolism in the puerperium must be considered (see section 4.6).
Upoštevati moramo zvečano tveganje za tromboembolijo v poporodni dobi (glejte poglavje 4. 6).
An increase in frequency or severity of headache (which may be prodromal of a cerebrovascular event) may be a reason for immediate discontinuation of combination contraceptives.
Zvečana pogostnost glavobolov ali močnejši glavoboli (ki lahko napovedujejo cerebrovaskularni dogodek) so lahko vzrok za takojšnje prenehanje uporabe kombiniranih kontraceptivov.
In case of suspected or confirmed thrombosis, hormonal contraceptive use should be discontinued.
Ob sumu na trombozo, ali če je le- ta potrjena, mora ženska prenehati z uporabo hormonskih kontraceptivov.
Tumours
7 Tumorji
An increased risk of cervical cancer in long-term users of COCs has been reported in some epidemiological studies, but there continues to be controversy about the extent to which this finding is attributable to the compounding effects of sexual behaviour and other factors such as human papilloma virus (HPV).
V nekaterih epidemioloških raziskavah so pri ženskah, ki so dalj časa jemale KPKS, poročali o zvečanem tveganju za raka na materničnem vratu, še vedno pa ni enotnega mnenja o tem, v kolikšni meri lahko to ugotovitev pripišemo kombiniranim učinkom spolnega vedenja in drugih dejavnikov, npr. papilomavirusu (HPV - Human Papilloma Virus).
7 A meta-analysis of 54 epidemiological studies reported that there is a slightly increased risk (RR = 1.24) of having breast cancer diagnosed in women who are currently using COCs.
Metaanaliza 54 epidemioloških raziskav kaže, da je pri ženskah, ki jemljejo KPKS, tveganje (RR = 1, 24) za raka na prsih nekoliko večje.
- Contraceptive efficacy may be reduced in women weighing equal or greater than 90 kg (see
- Pri ženskah, s telesno maso 90 kg ali več, se učinkovitost kontracepcije lahko zmanjša (glejte
sections 4.2 and 5.1).
poglavji 4. 2 in 5. 1).
- Women with hypertriglyceridaemia, or a family history thereof, may be at an increased risk of
- Pri ženskah s hipertrigliceridemijo ali hipertrigliceridemijo v družinski anamnezi, ki jemljejo
pancreatitis when using combination hormonal contraceptives.
kombinirane hormonske kontraceptive, lahko obstaja zvečano tveganje za pankreatitis.
- Although small increases of blood pressure have been reported in many women using hormonal
- Čeprav so poročali, da se je pri mnogih ženskah, ki uporabljajo hormonske kontraceptive, krvni
contraceptives, clinically relevant increases are rare.
tlak nekoliko zvišal, so klinično pomembna zvišanja redka.
If, during the use of a combination hormonal contraceptive in pre-existing hypertension, constantly elevated blood pressure values or a significant increase in blood pressure do not respond adequately to antihypertensive treatment, the combination hormonal contraceptive must be withdrawn.
Če se pri ženskah, ki že imajo hipertenzijo, med uporabo kombiniranih hormonskih kontraceptivov stalno povišane vrednosti krvnega tlaka ali pomembno zvišan krvni tlak ne odzovejo ustrezno na antihipertenzivno zdravljenje, morajo z uporabo kombiniranih hormonskih kontraceptivov prekiniti.
Combination hormonal contraceptive use may be resumed if normotensive values can be achieved with antihypertensive therapy.
Z uporabo kombiniranih hormonskih kontraceptivov lahko nadaljujejo, če z antihipertenzivnim zdravljenjem lahko dosežemo normalne vrednosti krvnega tlaka.
- The following conditions have been reported to occur or deteriorate with both pregnancy and
- Poročali so, da se tako med nosečnostjo kot tudi med jemanjem KPKS naslednja stanja bodisi
Jaundice and/ or pruritus related to cholestasis; gallstones; porphyria; systemic erythematosus; haemolytic ureamic syndrome; Sydenham’ s chorea; herpes gestationis; otosclerosis-related hearing loss.
pojavijo bodisi poslabšajo, niso pa dokazali, da so povezana z jemanjem KPKS: zlatenica in/ ali pruritus, povezan s holestazo, žolčni kamni, porfirija, sistemski eritematodes, hemolitičnouremični sindrom, Sydenhamova horea, pemfigoid (herpes gestationis), izguba sluha povezana z otosklerozo.
- Acute or chronic disturbances of liver function may necessitate the discontinuation of
- Zaradi akutnih ali kroničnih motenj v delovanju jeter bo morda treba prekiniti z uporabo
combination hormonal contraceptives until markers of liver function return to normal.
kombiniranih peroralnih kontraceptivov, dokler se vrednosti označevalcev jetrnih funkcij ne normalizirajo.
Recurrence of cholestatic-related pruritus, which occurred during a previous pregnancy or previous use of sex steroids necessitates the discontinuation of combination hormonal contraceptives.
Če se s holestazo povezan pruritus, ki se je pojavil že med prejšnjo nosečnostjo ali med predhodno uporabo kontracepcijskih steroidnih hormonov, ponovno pojavi, mora ženska z jemanjem kombiniranih hormonskih kontraceptivov prenehati.
- Although combined hormonal contraceptives may have an effect on peripheral insulin resistance
- Čeprav kombinirani hormonski kontraceptivi lahko vplivajo na periferno rezistenco za insulin in
and glucose tolerance there is no evidence for a need to alter the therapeutic regimen in diabetes during use of combined hormonal contraception.
toleranco za glukozo, ni dokaza, da bi bilo treba pri sladkorni bolezni med uporabo kombiniranih hormonskih kontraceptivov spreminjati režim zdravljenja.
- Worsening of endogenous depression, of epilepsy, of Crohn’ s disease and of ulcerative colitis
- Med uporabo KPKS so poročali o poslabšanju endogene depresije, epilepsije, Crohnove bolezni
has been reported during COC use.
in ulceroznega kolitisa.
- Chloasma may occasionally occur with the use of hormonal contraception, especially in users
- Pri uporabi hormonske kontracepcije se občasno lahko pojavi kloazma, še posebej pri ženskah,
with a history of chloasma gravidarum.
ki so imele kloazmo že prej med nosečnostjo.
Medical examination/ consultation
8 Zdravniški pregled/ posvetovanje
Prior to the initiation or reinstitution of EVRA a complete medical history (including family history) should be taken and pregnancy should be ruled out.
Pred začetkom ali ponovno uporabo obližev EVRA moramo pridobiti podrobno anamnezo (tudi družinsko) in izključiti nosečnost.
Blood pressure should be measured and a physical examination should be performed guided by the contraindications (see section 4.3) and warnings (see section 4.4).
Izmeriti moramo krvni tlak in opraviti zdravniški pregled upoštevajoč kontraindikacije (glejte poglavje 4. 3) in opozorila (glejte poglavje 4. 4).
The woman should also be instructed to carefully read the package leaflet and to adhere to the advice given.
Žensko moramo poučiti, da skrbno prebere navodilo za uporabo in upošteva dane nasvete.
8 The frequency and nature of subsequent examinations should be based on established guidelines and be adapted to the individual woman on the basis of clinical impression.
Pogostnost in narava nadaljnjih pregledov morata temeljiti na dokazanih smernicah in ju moramo na podlagi kliničnih ugotovitev prilagajati vsaki ženski posebej.
Women should be advised that hormonal contraceptives do not protect against HIV infections (AIDS) and other sexually transmissible diseases.
Ženske moramo poučiti, da hormonski kontraceptivi ne ščitijo pred okužbami z virusom HIV (AIDS) in drugimi spolno prenosljivimi boleznimi.
With all combination hormonal contraceptives, irregular blood loss (spotting or breakthrough bleeding) can occur, especially during the initial months of usage.
Pri vseh kombiniranih hormonskih kontraceptivih se lahko pojavi nenormalna krvavitev (kapljična krvavitev ali vmesna krvavitev), zlasti v prvih mesecih njihove uporabe.
For this reason, a medical opinion on irregular blood loss will only be useful after an adjustment period of approximately three cycles.
Zdravniško mnenje o nenormalni krvavitvi bo zato smotrno šele po obdobju prilagajanja, ki traja približno 3 cikluse.
If breakthrough bleeding persists, or breakthrough bleeding occurs after previously regular cycles, while EVRA has been used according the recommended regimen, a cause other than EVRA should be considered.
Če se po ciklusih, ki so bili v preteklosti redni, krvavitev kljub predpisanem odmerku ne ustavi, oz. se le- ta pojavi, čeprav je ženska obliže EVRA uporabljala po priporočenem režimu, moramo razmisliti o drugem vzroku.
In some women withdrawal bleeding may not occur during this patch free period.
Pri nekaterih ženskah se med premorom prekinitvena krvavitev ne pojavi.
If EVRA has been taken according to the directions described in section 4.2, it is unlikely that the woman is pregnant.
Če je ženska obliže EVRA uporabljala skladno z navodili, opisanimi v poglavju 4. 2, najverjetneje ni noseča.
Herbal preparations containing St John’ s Wort (Hypericum perforatum) should not be used while taking EVRA (see section 4.5)
Med uporabo obližev EVRA ženska ne sme jemati zeliščnih pripravkov, ki vsebujejo šentjanževko (Hypericum perforatum) (glejte poglavje 4. 5).
Influence of other medicinal products on EVRA
Vpliv drugih zdravil na obliž EVRA
Medicinal product interactions, which result in an increased clearance of sex hormones can lead to breakthrough bleeding and hormonal contraceptive failure.
Posledica interakcij z zdravili, ki zvečajo očistek spolnih hormonov, je lahko krvavitev kljub predpisanem odmerku in neučinkovitost hormonskih kontraceptivov.
This has been established with hydantoins, barbiturates, primidone, carbamazepine and rifampicin; bosentan, oxcarbazepine, topiramate, felbamate, ritonavir, griseofulvin, modafinil and phenyl butazone are also suspected.
To so dokazali pri hidantoinih, barbituratih, primidonu, karbamazepinu in rifampicinu; domnevajo, da to velja tudi za bosentan, okskarbazepin, topiramat, felbamat, ritonavir, grizeofulvin, modafinil in fenilbutazon.
The mechanism of these interactions appears to be based on the hepatic enzyme inducing properties of these medicinal products.
Zdi se, da mehanizem teh interakcij temelji na indukciji jetrnih encimov.
Maximal enzyme induction is generally not seen for 2-3 weeks but may be sustained for at least 4 weeks after cessation of therapy.
Maksimalne encimske indukcije običajno ne opazimo 2- 3 tedne, traja pa lahko še najmanj 4 tedne po prekinitvi uporabe obliža.
The herbal preparation of St John’ s Wort (Hypericum perforatum) should not be taken concomitantly with this medicinal product as this could potentially lead to a loss of contraceptive effect.
Hkrati z uporabo tega obliža ženska ne sme jemati zeliščnih pripravkov iz šentjanževke (Hypericum perforatum), saj lahko zmanjšajo kontracepcijsko učinkovitost obliža.
Breakthrough bleeding and unintended pregnancies have been reported.
Poročali so o vmesni krvavitvi in nenačrtovanih nosečnostih.
This is due to induction of metabolising enzymes by St John’ s Wort.
To je posledica indukcije metabolnih encimov s šentjanževko.
The inducing effect may persist for at least 2 weeks after cessation of treatment with St John’ s Wort.
Učinek indukcije lahko traja še najmanj 2 tedna po prekinitvi zdravljenja s šentjanževko.
Contraceptive failures have also been reported with antibiotics, such as ampicillin and tetracyclines.
O neučinkovitosti kontracepcije so prav tako poročali pri jemanju antibiotikov (npr. ampicilina in tetraciklinov).
The mechanism of this effect has not been elucidated.
Mehanizma tega učinka niso pojasnili.
In a pharmacokinetic interaction study, oral administration of tetracycline hydrochloride, 500 mg four times daily for 3 days prior to and 7 days during wear of EVRA, did not significantly affect the pharmacokinetics of norelgestromin or EE.
V raziskavi farmakokinetike interakcij so ugotovili, da peroralno uživanje tetraciklinijevega klorida v odmerku 500 mg 4- krat na dan 3 dni pred in 7 dni med uporabo obliža EVRA ni pomembno vplivalo na farmakokinetiko norelgestromina ali etinilestradiola.
Women on treatment with any of these medicinal products should temporarily use a barrier method in addition to EVRA or choose another method of contraception.
9 Ženske, ki se zdravijo s katerimkoli od teh zdravil, morajo poleg obližev EVRA začasno uporabljati še mehansko metodo kontracepcije ali pa izbrati drugo metodo kontracepcije.
With microsomal enzyme-inducing medicinal products, the barrier method should be used during the time of concomitant administration of these medicinal products and for 28 days after their discontinuation.
Kadar ženska sočasno jemlje zdravila, ki inducirajo mikrosomske encime, in še 28 dni po prenehanju jemanja, mora uporabljati tudi mehansko metodo kontracepcije.
Women on treatment with antibiotics (except tetracycline) should use the barrier method until 7 days after discontinuation.
Ženske, zdravljene z antibiotiki (razen s tetraciklini), morajo mehansko metodo preprečevanja nosečnosti uporabljati še 7 dni po prenehanju zdravljenja.
If concomitant medicinal product administration runs beyond the 3 weeks of patch treatment, a new treatment cycle should be started immediately without having the usual patch-free interval.
Če ženska med uporabo obliža dlje kot tri tedne sočasno jemlje še drugo zdravilo, mora brez običajnega premora takoj pričeti z novim ciklusom uporabe obliža.
9 For women on long-term therapy with hepatic enzyme inducers, another method of contraception should be considered.
Pri ženskah, ki jih dalj časa zdravimo z induktorji jetrnih encimov, moramo razmisliti o drugi metodi kontracepcije.
Influence of EVRA on other medications
Vpliv obliža EVRA na druga zdravila
Progestogens and estrogens inhibit a variety of P450 enzymes (e. g., CYP 3A4, CYP 2C19) in human liver microsomes.
CYP 3A4, CYP 2C19).
However, under the recommended dosing regimen, the in vivo concentrations of norelgestromin and its metabolites, even at the peak serum levels, are relatively low compared to the inhibitory constant (Ki), indicating a low potential for clinical interaction.
Ob upoštevanju priporočenega režima odmerjanja so in vivo koncentracije norelgestromina in njegovih metabolitov sorazmerno nizke (tudi pri najvišji plazemski koncentraciji) v primerjavi z inhibitorno konstanto (Ki), kar kaže na nizek potencial za klinično interakcijo.